BIOGY (BioGaia AB) Cyclically Adjusted Revenue per Share: $ (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BIOGY BioGaia AB BIOGY
99 GF Score
Price $12.45
GF Value $11.90
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is BioGaia AB Cyclically Adjusted Revenue per Share?

BioGaia AB BIOGY 99 Cyclically Adjusted Revenue per Share is $ as of Jun. 2026. GuruFocus rates BIOGY with a GF Score™ of 99/100 and a GF Value™ of $11.90 (Fairly Valued). The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

BioGaia AB's adjusted revenue per share for the three months ended in Jun. 2026 was $0.465. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $ for the trailing ten years ended in Jun. 2026.

During the past 12 months, BioGaia AB's average Cyclically Adjusted Revenue Growth Rate was 8.30% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 9.70% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 11.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of BioGaia AB was 12.90% per year. The lowest was 9.70% per year. And the median was 11.00% per year.

As of today (2026-09-21), BioGaia AB's current stock price is $12.45. BioGaia AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was $. BioGaia AB's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of BioGaia AB was 18.84. The lowest was 8.61. And the median was 12.68.


BioGaia AB  (OTCPK:BIOGY) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of BioGaia AB was 18.84. The lowest was 8.61. And the median was 12.68.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


BioGaia AB Cyclically Adjusted Revenue per Share Related Terms


BioGaia AB Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for BioGaia AB's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioGaia AB Cyclically Adjusted Revenue per Share Chart

BioGaia AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

BioGaia AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

BIOGY vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, BioGaia AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioGaia AB Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BioGaia AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where BioGaia AB's Cyclically Adjusted PS Ratio falls into.


BIOGY
99GF Score
BioGaia AB BIOGY
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioGaia AB Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, BioGaia AB's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.465/134.6100*134.6100
=0.465

Current CPI (Jun. 2026) = 134.6100.

BioGaia AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.170 101.138 0.226
201612 0.176 102.022 0.232
201703 0.183 102.022 0.241
201706 0.208 102.752 0.272
201709 0.209 103.279 0.272
201712 0.236 103.793 0.306
201803 0.223 103.962 0.289
201806 0.267 104.875 0.343
201809 0.225 105.679 0.287
201812 0.267 105.912 0.339
201903 0.215 105.886 0.273
201906 0.272 106.742 0.343
201909 0.201 107.214 0.252
201912 0.249 107.766 0.311
202003 0.218 106.563 0.275
202006 0.291 107.498 0.364
202009 0.172 107.635 0.215
202012 0.229 108.296 0.285
202103 0.238 108.360 0.296
202106 0.239 108.928 0.295
202109 0.199 110.338 0.243
202112 0.230 112.486 0.275
202203 0.301 114.825 0.353
202206 0.290 118.384 0.330
202209 0.242 122.296 0.266
202212 0.253 126.365 0.270
202303 0.347 127.042 0.368
202306 0.296 129.407 0.308
202309 0.291 130.224 0.301
202312 0.276 131.912 0.282
202403 0.352 132.205 0.358
202406 0.356 132.716 0.361
202409 0.288 132.304 0.293
202412 0.335 132.987 0.339
202503 0.339 132.825 0.344
202506 0.414 133.699 0.417
202509 0.339 133.480 0.342
202512 0.463 133.380 0.467
202603 0.403 133.550 0.406
202606 0.465 134.610 0.465

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $ mean?
BioGaia AB (BIOGY) has a Cyclically Adjusted Revenue per Share of $ as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on BioGaia AB and its competitors.
Is BioGaia AB's Cyclically Adjusted Revenue per Share too high?
BioGaia AB's current Cyclically Adjusted Revenue per Share is $. Overall, BioGaia AB has a GF Score™ of 99/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioGaia AB's Cyclically Adjusted Revenue per Share compare to ZTS?
BioGaia AB's Cyclically Adjusted Revenue per Share of $ can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on BioGaia AB and its competitors. BioGaia AB's current Cyclically Adjusted Revenue per Share is $. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioGaia AB stock overvalued right now?
Based on GuruFocus' analysis, BioGaia AB (BIOGY) is currently considered Fairly Valued. The stock's GF Value™ is $11.90, compared to a current price of $12.45 — trading 4.6% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is $. BioGaia AB's overall GF Score™ is 99/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For BioGaia AB (BIOGY), the current Cyclically Adjusted Revenue per Share is $ as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioGaia AB (BIOGY) Overvalued in 2026?

Based on GuruFocus' analysis, BioGaia AB stock appears to be overvalued. The current stock price of $12.45 is trading 4.6% above its estimated GF Value™ of $11.90. GuruFocus considers BioGaia AB to be Fairly Valued.

Key valuation signals for BIOGY:

  • Cyclically Adjusted Revenue per Share: $
  • GF Value™: $11.90 vs. price of $12.45 (4.6% above fair value)
  • GF Score™: 99/100 with 1 warning sign

No single metric tells the full story. See the BIOGY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BioGaia AB Business Description

Address Kungsbroplan 3A, Stockholm, SWE, SE-112 27
BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions: EMEA, the Americas, and APAC (Asia-Pacific, Australia, and New Zealand).
99GF Score

Get the complete analysis for BIOGY

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.45
Price
$11.90
GF Value